Emerging Biological Therapies on the Horizon for β-Thalassemia

Download this slideset for an expert-curated overview of emerging biological therapies for β-thalassemia, including review of the latest clinical data leading to the recent approval of the erythroid maturation agent luspatercept for transfusion-dependent disease.
Maria Domenica Cappellini, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 1.12 MB
Released: December 6, 2019

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Celgene Corporation

Related Content

Clinical Care Options (CCO) expert faculty Guy Young, MD, on the evolution of prophylaxis therapy for hemophilia A and adherence challenges with young adult patients

Guy A. Young, MD Released: September 22, 2021

Clinical commentary from European hematology experts on key clinical trials presented at the virtual EHA 2021 meeting, from Clinical Care Options (CCO)

Charles Craddock, CBE, FRCP (UK), FRCPath, DPhil, FMedSci María-Victoria Mateos, MD, PhD Lydia Scarfò, MD Ali T. Taher, MD, PhD, FRCP Released: July 28, 2021

Downloadable slideset with highlights from key blood cancers and nonmalignant blood disorders as presented at EHA Virtual Congress 2021, from Clinical Care Options (CCO)

Charles Craddock, CBE, FRCP (UK), FRCPath, DPhil, FMedSci María-Victoria Mateos, MD, PhD Lydia Scarfò, MD Ali T. Taher, MD, PhD, FRCP Released: July 16, 2021

Dr. Corey S. Cutler shares his views on current and future graft-vs-host disease (GVHD) therapies in this commentary from Clinical Care Options (CCO)

Corey S. Cutler, MD, MPH, FRCPC Released: April 27, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue